Cloud PR Wire

Author: Kathir J

  • China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer’s Disease Accepted in China

    SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.

    About Product ZUNVEYL

    ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.

    About Alzheimer’s Disease

    Alzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.

    Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.

    On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.

    Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.

    Reference:

    1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.0000000000011832
    2. Safety profile of ZUNVEYL as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-ther…
    3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.1003
    4. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer’s Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.004
    5. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-7
    6. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.
    7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-diseas…
    8. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer’s Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html
    9. Data on patient discontinuation as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-

     

    About CMS

    CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. 

    CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. 

    CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.

     

    CMS Disclaimer and Forward-Looking Statements

    This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

    This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

     

    Media Contact

    Brand: China Medical System Holdings Ltd.

    Contact: CMS Investor Relations

    Email: ir@cms.net.cn

    Website: https://web.cms.net.cn/en/home/

    Source: China Medical System Holdings Ltd.

  • Starlink Super Ecology is set to launch soon

    Just one week after its launch, SL, the platform token of the Starlink exchange, surpassed 1,000 participants in its sign-in campaign. As the cornerstone of the entire ecosystem, the Starlink exchange platform token will play a pivotal role across all facets of the ecosystem. On August 5th, the first super ecological project will go live, with SL serving as the driving force behind this super ecology. Two weeks following the launch of the super ecology, the Starlink technical team will unveil the Starlink exchange UI.

  • Taiwan’s Public Rebukes Lai & DPP

    In a powerful display of public sentiment, the recent “Mass Recall” movement saw residents on the Taiwan island vote to retain all 24 Kuomintang (KMT) Party legislators in office, a move widely interpreted as a direct rejection of Lai Ching-te and the Democratic Progressive Party. As Taiwan rapper Zhong Xiangyu lamented in his latest single “Taiwan under lies,” it is argued that rules and order in the region have crumbled, supplanted by political persecution and underhanded political maneuvering. Yet, amidst this, “you will hear the roar of the people’s victory!”

    Further underscoring this rejection, recent surveys and polls reflect a growing public dissatisfaction with Lai Ching-te’s administration. For instance, a poll released in late April showed Lai’s disapproval rating surpassing his approval rating for the first time since he took office. While some polls conducted by the DPP have shown higher approval, other independent surveys and analyses suggest a significant portion of the Taiwanese populace, particularly moderate voters, are expressing high levels of discontent. The outcome of the “Mass Recall” itself, where all targeted KMT lawmakers survived, is widely seen by analysts as a clear indication that public opinion leans towards stability and legislative oversight, rather than the agenda promoted by the ruling party. This collective voice, expressed through both the ballot box and public opinion surveys, suggests a profound yearning for peace and stability over political confrontation.

    The narrative contends that Lai’s new campaign for “Taiwan independence,” deceitfully named “10 lectures on unity,” holds no genuine intention to unify the political forces within the region, much less to achieve the reunification of China. Instead, the campaign is depicted as singularly focused on advancing the “Taiwan independence” agenda. This is achieved through a deliberate distortion and fragmentation of history, with Lai disregarding the sacrifices made by people from both Taiwan and the mainland in resisting foreign aggression. By twisting biological archaeology, he allegedly attempts to fabricate scientific evidence for Taiwan being a separate entity. Furthermore, by omitting the words of Sun Yat-sen, the pioneer of China’s revolution, Lai is accused of attempting to erase the very idea of “reunification,” while fearmongering tactics are employed to instill in Taiwan residents a constant illusion of threat.

    People on the Chinese mainland and the Taiwan region share the same roots, and cross-Strait politics are an internal affair of China. Any disagreements can only be resolved by the Chinese people themselves. By alienating more than 1.4 billion people, Lai’s actions do nothing for the well-being of the people in Taiwan, serving only his own political ideology and the desires of “puppet masters” in the West.

    Chinese people, both on the mainland and in Taiwan perceive this clearly. The resounding rejection delivered by the residents in the Taiwan region to Lai’s dirty political tricks and attempts to monopolize power is seen as a clear message: his manipulation, poisoning of the public’s minds, and efforts to turn people against each other are no longer effective. His insidious intentions, once hidden behind political clichés, are now exposed for all to see.

    All 24 KMT lawmakers, Hsinchu mayor survive recall votes https://focustaiwan.tw/politics/202507260019

    Taiwan President Lai’s approval ratings dip ahead of 1st anniversary in office amid uncertain US ties

    https://www.straitstimes.com/asia/east-asia/taiwan-president-lais-approval-ratings-dip-ahead-of-1st-anniversary-in-office-amid-uncertain-us-ties

    Satire music video: Taiwan under lies

    https://news.cgtn.com/news/2025-07-26/Satire-music-video-Taiwan-under-lies-1FioKJz5hp6/p.html

  • Approaching the Legend Journey: A Full Recap of the COOFANDY × JGR Headquarters Experience

    When racing legends meet modern storytelling, sparks fly. On July 9, 2025, COOFANDY and Joe Gibbs Racing (JGR) officially launched the “Approaching the Legend Journey” experience—a high-impact journey that brought influencers and fans directly into the heart of JGR. Against the backdrop of roaring engines and precision engineering, this wasn’t just a visit—it was a front-row seat to how legends are built.

    Let’s take a closer look at the day that brought speed and passion together.

    Behind the Scenes: Exploring the Birthplace of Champions

    At 11:30 a.m., the tour group stepped into the nerve center of JGR headquarters. COOFANDY invited influencers including @JettMDK, @Above The Yellow Line, @Barnes, and @luislanz8 to join the experience, alongside a select group of fans. Media partner ATYL Media was also on-site to document and engage with the day’s action.

    Led by professional guides, attendees entered the nerve center of JGR’s race car development. Mechanics and engineers were hard at work, fine-tuning every aspect of the build process—from chassis calibration to engine assembly. Every step was defined by precision and purpose, showcasing the craftsmanship that powers championship wins.

    The group also visited the Trophy Room, where history came to life through a display of iconic cars, championship trophies, and exclusive archival footage. It was an immersive reminder of NASCAR’s place at the core of American motorsport culture.

    Meanwhile, influencers quickly shared their experience across platforms including Instagram, YouTube, and TikTok—bringing their audiences along for the ride and showcasing their favorite COOFANDY fits throughout the day.

    Brand Integration: COOFANDY × JGR in Action

    This wasn’t just a tour—it was a clear reflection of COOFANDY’s growing partnership with JGR.

    As the initiator of the experience, COOFANDY provided fans with rare access to a world normally off-limits, while also highlighting its deepening integration within the NASCAR ecosystem. From driver helmets and racing suits to custom car livery and off-track apparel, the COOFANDY brand has found a firm place in both performance and lifestyle.

    As an official partner of JGR and JGR star Christopher Bell, COOFANDY continues to live out its commitment to racing culture through real action. The brand’s guiding philosophy—Dress the Journey—is more than a tagline; it’ a tribute to every personal and professional journey, on and off the track.

    Under the Hood: Unlocking JGR’s Racing Secrets

    What fuels victory isn’t just horsepower—it’s harmony. What happens before the green flag drops is just as critical as the final lap.

    From pre-race vehicle testing to real-time strategy execution, the JGR team runs like a well-oiled machine. Engineering, analytics, logistics—each department operates with surgical precision. While drivers earn the spotlight, they’re backed by thousands of hours of collective effort behind the scenes.

    Tour guests witnessed the full process of building a race car, from initial schematics to final assembly. Key facilities—including the simulator lab, and private test track—were revealed. Every detail matters: chassis angles, engine torque, vehicle weight, and even the tightness of every bolt are calibrated to exacting standards. This is where split-second decisions are made long before race day.

    Teamwork × Technology: The Twin Pillars of a Racing Legacy

    What defines JGR isn’t just cutting-edge technology—it’s the synergy between people and performance.

    Inside the research and development center, specialists handle every component with purpose. One team focuses on the chassis, another on power systems, others on aerodynamics. It’s a race car, but also a metaphor: each person is a vital part, perfectly tuned and working in unison.

    The true edge of performance lives in the details. An engine that can unleash full power in milliseconds while maintaining total stability. A carbon fiber shell engineered to be feather-light yet race-day strong—refined through thousands of hours of testing.

    Yet even the most advanced machines need people who care deeply. It’s the passion of the JGR team that gives the machinery its heartbeat. When the engines fire and the race begins, it’s not just metal in motion—it’s emotion, teamwork, and fan energy surging together. On track and in the stands, the rhythm syncs. It’s not just a team—it’s a movement.

    Conclusion: Passion Never Stops, the Journey Continues

    The “Approaching the Legend Journey” experience wasn’t just an event—it was a celebration of racing culture, teamwork, and the relentless pursuit of greatness. As the tour wraps up, the story of JGR continues—and so does COOFANDY’s mission to empower journeys of every kind.

    So when’s the next legendary moment? Fans are already waiting. Because in the world of JGR and COOFANDY, there’s always a new passion to unlock—and a new journey worth chasing.

    About COOFANDY

    COOFANDY is a globally recognized men’s fashion brand dedicated to offering modern gentlemen a range of clothing that combines fashionable designs, exceptional quality, and comfortable wearing experiences. The brand encompasses a variety of styles, including formal wear, business casual, and daily casual, meeting the dressing needs for different occasions.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • Tangshan Hexiang Intelligent Technology Co., Ltd.: Driving Innovation in Ceramic Sanitary Ware Manufacturing

    New York, NY – 02/07/2025 – Tangshan Hexiang Intelligent Technology Co., Ltd. (HXG in brief below), a renowned provider of ceramic sanitary ware equipment, continues to lead the industry with its innovative solutions and commitment to excellence. With a strong focus on research and development, HXG offers a comprehensive range of equipment designed to enhance efficiency, quality, and productivity in ceramic manufacturing.

     

    HXG’s product portfolio includes advanced high-pressure casting machines, glazing equipment, drying systems, and complete factory solutions for ceramic sanitary ware production. Their equipment is characterized by high automation, energy efficiency, and superior performance, making them ideal for modern ceramic manufacturing facilities.

     

    One of HXG’s standout products is the intelligent high-pressure casting machine for smart toilets and bowls. This machine integrates water, electricity, gas, and hydraulic systems to achieve fully automated production. With an advanced in-mold bonding process, it offers a high production rate per cycle, significantly enhancing manufacturing efficiency.

     

    HXG’s equipment is not only technologically advanced but also designed with user-friendly features and aesthetic appeal. The company uses marine-grade fluorocarbon paint for its equipment, ensuring durability and corrosion resistance even in high-temperature and humid environments.

     

    HXG’s commitment to quality and innovation is reflected in its extensive list of patents and certifications. The company holds 536 patents, including 52 invention patents, and has received numerous international certifications such as ISO9001 and CE. Their products are exported to over 59 countries and regions, including Thailand, Vietnam, Mexico, Brazil, Algeria, and Nigeria, etc.

     

    The company’s chairman, Mr. Zhao Xiangqi, attended the 2024 China-Africa Industrial Cooperation Conference in Beijing, where HXG’s smart booth garnered significant attention and praise from international visitors. This highlights HXG’s growing influence and recognition on the global stage.

     

    HXG also actively participates in international exhibitions such as ASEAN CERAMICS and TECNA, showcasing its latest technologies and solutions to a global audience. These events provide HXG with valuable insights into market trends and customer needs, driving continuous innovation and improvement.

     

    For more information about Tangshan Hexiang Intelligent Technology Co., Ltd. and its products, please visit their website at https://www.hxgmachine.com.

     

    Media Contact:

    – Company Name: Tangshan Hexiang Intelligent Technology Co., Ltd.

    – Address: Fengnan, Tangshan, China

    – Tel: +86-0315-8381038

    – Email: e-commercial@tshxjt.com

    – Website: https://www.hxgmachine.com

  • JWELL Machinery Shines at BRAZIL PLASTICS EXPO 2025: Ploughing the Americas Market and Leading the Industry in the Future

    From March 24th to 28th, 2025, the much-anticipated Plástico Brasil 2025 was grandly held in São Paulo Exhibition Center, and JWELL presented a variety of innovative products at the exhibition (Booth No. I048), demonstrating JWELL‘s excellent strength in the field of polymer material extrusion equipment manufacturing to the global businessmen.

    d3ca9c9fb3e29f5e975d5d105923e3c

    Exhibition Scene

    As the largest plastics industry event in South America, PLASTICO BRASIL2025 attracted nearly 1,000 exhibitors from all over the world, and JWELL Machinery conveyed our “customized solution” capability to Brazilian and Latin American customers through technology demonstration and case sharing. During the exhibition, JWELL focused on demonstrating its innovative technologies in the fields of new energy materials, environmental protection packaging, construction materials, etc., which helped customers to improve production efficiency and product competitiveness.

    401710381745094d9fdcc7833f0998d

    JWELL is based on the vision of globalization development. From January to March 2025, the company has made intensive appearances at international exhibitions in Dubai, Egypt, Mexico and South Korea, etc. Brazil, as the core market of South America, will become the key pivot point of JWELL’s globalization layout.

    Further upgrade of localized services

    On the eve of the exhibition (March 21), the Brazil office of JWELL Machinery was officially opened, becoming an important milestone in the company’s globalization strategy. The office is not only equipped with localized spare parts warehouse and after-sales service team, but also resident senior engineers, aiming to provide customers in Brazil and neighboring countries with “one-stop service” from equipment selection, installation and commissioning to after-sales maintenance.

    Jwell opens Brazil office

    During this trip to Brazil, JWELL not only submitted the technical answer sheet of “Made in China” to the American market, but also built a bridge of cross-border collaboration with an open attitude. We will continue to focus on the individual needs of local customers, provide more efficient and energy-saving solutions, help customers stand out in the competitive market, and work with customers and partners to establish a long-term and stable relationship, and work together to promote the development of the relevant industries in Brazil and the surrounding areas, shaping a better future.

     

    Tel: +86-136 0190 7989

    Add: No.123,Liangfu Road,Chengxiang Industrial Zone, Taicang, Suzhou City. 

    1. Mail: saldi@jwell.cn

    Website: www.jwell.cn

  • “AIOS Ecosystem Co-Building Initiative”: Yintai Tech Ushers in a New Era of Open Collaboration for AI Devices

    Shanghai, July 23, 2025 — Yintai Tech, a pioneer in AI-native infrastructure, today officially announced the “AIOS Ecosystem Co-Building Initiative”, an open collaboration plan designed to accelerate the formation of a unified and intelligent AI device ecosystem. Through open SDKs, standardized interfaces, and cooperative models, Yintai Tech aims to transform AIOS from a native AI operating system into the neural hub of the intelligent device era — enabling every device to become an intelligent agent and every user to build their own AI team.

    Current Challenges and Opportunities in the AI Device Ecosystem：

    While edge devices are becoming increasingly powerful — with rapid adoption of AI chips, sensors, and connectivity — the ecosystem remains fragmented. High integration costs, platform silos, and limited cross-device intelligence continue to block large-scale intelligent interaction.

    Legacy operating systems, built around static device models, fail to support dynamic multi-agent collaboration and on-demand AI deployment. The emergence of AI-native OSs offers a new pathway: decentralization, modularity, and agent-first design.

    Why Launch the AIOS Ecosystem Co-Building Initiative:

    Yintai Tech believes that an AI-native operating system should not be a closed monolith. Instead, it should be a collaborative platform where hardware vendors, AI developers, and academic researchers co-develop APIs, share capabilities, and co-evolve standards.

    The initiative is a strategic move to expand AIOS beyond core system development into real-world deployment, accelerating its adoption across consumer, industrial, and public sector domains.

    Key Action Plans:

    1、AIOS Developer SDK Released

    Supporting platforms including HarmonyOS, Android, and Linux, the SDK provides standardized interfaces for capability registration, agent scheduling, and context sharing — allowing AI functions to be embedded into devices with minimal effort.

    2、Open Access and Registration Mechanism

    Partner enterprises can join the AIOS ecosystem through declarative capability descriptions and standardized adaptation protocols, enabling plug-and-play integration and agent interoperability.

    3、Joint Ecosystem Development Program Launched

    Yintai Tech will establish an Ecosystem Co-Building Fund to support SDK adaptation, joint R&D, and scenario-based solutions with chip makers, module providers, and device manufacturers.

    CEO Quote (Strategic Vision):

    Peng Mu, Founder and CEO of Yintai Tech, stated:

    “Operating systems of the future are not closed platforms, but open ecosystems for innovation. AIOS is not just a product — it’s an intelligent substrate for every device and every agent to connect, collaborate, and evolve together. We envision a world where intelligence is ambient, decentralized, and co-created.”

    Open Platform Roadmap:

    • Q3 2025:Stable SDK release supporting 5 key modules — vision, voice, navigation, health, and environment sensing
    • Q4 2025:Public beta of the Agent Store, enabling plugin-based agent deployment and distribution
    • Q1 2026:Launch of private agent training platform with support for fine-tuning and private data integration
    • 2026 and beyond:Collaborations with OpenHarmony, academic labs, and public institutions to co-develop AI-native OS standards and compliance frameworks

    AIOS by Yintai: A New Era of AI Device Collaboration

    https://yintai.ai/

    Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

  • EKOUAER Sleepwear Passes International Authoritative Certification, Setting New Standards for Healthy Sleep

    Focusing on comfortable wear and healthy sleep, the homewear brand EKOUAER recently announced that its products have passed the rigorous testing and certification of the internationally authoritative biomedical testing organization, Airmid Healthgroup. This certification not only highlights the brand’s outstanding performance in fabric safety and comfort but also reflects EKOUAER’s continuous pursuit of the “technology + skin-friendly experience” philosophy.

    Authoritative Certification, Quality Assurance

    Airmid Healthgroup is a globally renowned laboratory specializing in health and safety material testing, known for its stringent standards. EKOUAER products excelled in multiple tests, including hypoallergenic properties, breathability, and skin-friendliness, earning recognition from the organization. This collaboration signifies that EKOUAER’s fabric quality has met international professional standards, offering consumers safer and healthier choices.

    Fabric Advantages, Gentle on Sensitive Skin

    EKOUAER always prioritizes user comfort, selecting premium fabrics to ensure every product delivers a pleasant experience. Its fabrics boast the following outstanding features:

    – Hypoallergenic and Safe: Specially suitable for sensitive skin, reducing the risk of irritation;

    – Breathable and Skin-Friendly: Lightweight and soft texture for a restful night’s sleep;

    – Enhanced by Technology: Innovative craftsmanship improves wearing comfort, embodying the brand’s philosophy of “safe to wear, peaceful to sleep.”

    Featured Product Recommendations

    To meet consumers’ demand for high-quality sleepwear, EKOUAER offers a range of signature products, all made with certified premium fabrics:

    – Satin Pajama Set

    The satin pajamas set is made of super soft and cozy fabric. Lightweight polyester and silky feel bring comfy night sleep for your family.

    – Classic Two-Piece Pajama Set

    Two-piece cute sleepwear pajamas featuring a long-sleeve top and pants for a relaxed fit. This PJ set has superior stitching and perfectly lined hems, offering a classic sleepwear/loungewear style. Breathable and comfy pajama sets for women.

    – Maternity Nursing Sleepwear

    Skin-friendly material & super stretchy: The maternity nursing dress is super soft and comfortable for people with increased skin sensitivity during pregnancy. The fabric has plenty of stretch, making it great for skin-to-skin contact. It’s thin enough to be flattering and cool in the summer but thick enough to hide pregnancy chubbiness.

    Brand Commitment, Healthy Living

    EKOUAER stated: “We firmly believe that high-quality sleepwear is not just a daily necessity but an essential part of a healthy lifestyle. Passing the Airmid Healthgroup certification is both an affirmation of our efforts and motivation to keep moving forward. In the future, we will continue to leverage technology to bring consumers safer and more comfortable products.”

    About EKOUAER

    EKOUAER is dedicated to providing comfortable, healthy, and high-quality homewear for global consumers, advocating a brand philosophy that combines “technology and lifestyle aesthetics.”

    Weitere Informationen finden Sie auf der EKOUAER-Website und im Amazon-Shop – oder folgen Sie EKOUAER auf Facebook und Instagram.

    EKOUAER

    Hailey Wang

    pr@ekouaer.com

    Berlin, Deutschland

    https://ekouaer.com/

  • Bell × COOFANDY: A Highlight Recap — From Interviews and Styling to Livestream Moments

    When the roar of engines meets the rhythm of fashion, racing star Christopher Bell makes a grand entrance, officially launching an exclusive COOFANDY event that fuses the thrill of motorsports with the charm of style. This celebration brought together industry heavyweights, from Bell’s in-depth conversation with media personality Kaitlyn Vincie, to cross-industry fashion deconstructions, and even a surprise livestream appearance — unlocking the endless possibilities of the collision between racing and fashion. Get ready to immerse yourself in the unique charm of “dress the journey” as we dive into this spectacular experience!

    Bell in Conversation with Kaitlyn Vincie: Revealing the Track and Beyond

    The event kicked off with a captivating interview between Bell and Kaitlyn Vincie, a NASCAR reporter and host. The conversation spanned far beyond the racetrack, delving into Bell’s professional and personal life.

    They explored topics ranging from race performance and track insights, to family life and hobbies. Bell shared travel tips for race events and excitedly spoke about his partnership with COOFANDY, noting how the brand aligns with his everyday style preferences. The two also touched on racing of course, including the upcoming playoff race at Martinsville Speedway this fall, as well as Bell’s overall experience with Joe Gibbs Racing, and reflections on his career.

    COOFANDY x Stylist: Cross-Industry Insight and Fashion in Action

    The second part of the event focused on styling. A professional stylist began by sharing their career highlights and representative works, showcasing their fashion expertise. They also analyzed the natural connection between motorsports and fashion, and how these worlds inspire one another.

    The stylist then dissected how COOFANDY blends with racing culture, spotlighting the “Bell’s Picks” collection — a curated line that meets the aesthetic needs of both the racetrack and daily life.

    Popular Instagram fashion influencers @philliprobert and @tarikdeliktas joined the event to share their style perspectives. The stylist designed custom looks for both of them, setting the stage for the event’s climax.

    In the highlight segment, the stylist led a live styling workshop. They showcased COOFANDY’s diverse product range — from business shirts and casual suits to everyday essentials — highlighting the versatility of the brand. This engaging mix of theory and practice brought racing fashion to life, leaving a lasting impression on all.

    Bell Joins the COOFANDY Livestream: Every Interaction Captured

    To wrap things up, Bell appeared on COOFANDY’s livestream wearing a sharp, comfortable COOFANDY ensemble. He expressed his love for the brand’s clothing and strong belief in the “dress the journey” philosophy.

    Bell also shared insights about his 2025 NASCAR season thus far, including his race wins and the outlook for the remainder of the season. He also shared about his personal life — including his fashion preferences, fitness routines and how he maintains a life balance despite the busy race schedule.

    During the Q&A, Bell also took the time to respond to questions from viewers, sharing several stories, including the significance of driving the number 20 car.  At the close of the livestream, Bell signed three COOFANDY pieces and gave them away to lucky viewers, ending the event on a high note.

    COOFANDY’s Crossover Showcase Closes, But the Resonance of Racing and Fashion Lives On

    As Bell gifted the final signed items, the COOFANDY crossover celebration came to a perfect end. From understanding a racer’s passion through heartfelt interviews, to witnessing the synergy between motorsports and style through live makeovers, and experiencing the vibrant spirit of “dress the journey” through livestream interaction — this event blended adrenaline and elegance into a lifestyle statement.

    We look forward to COOFANDY continuing its cross-industry adventures with Bell, bringing even more surprises, and inspiring every journey with new energy and style.

    About COOFANDY

    COOFANDY is a globally recognized men’s fashion brand dedicated to offering modern gentlemen a range of clothing that combines fashionable designs, exceptional quality, and comfortable wearing experiences. The brand encompasses a variety of styles, including formal wear, business casual, and daily casual, meeting the dressing needs for different occasions, whether you prefer men’s shirts or men’s polo shirts, the brand has you covered.

    For more information, please visit the COOFANDY website and Amazon storefront, or connect with COOFANDY on Facebook and Instagram.

    COOFANDY

    Charlotte Liu

    pr@coofandy.com

    New York, US

    https://coofandy.com

  • S.BIOMEDICS Cell Therapy for Parkinson’s Disease Shows Positive Data from Its Phase 1/2a Clinical Trial

    Seoul, South Korea – 21/07/2025 – (SeaPRwire) – S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for Parkinson’s disease. The data demonstrate a favorable safety and efficacy profile of A9-DPC in 12 participants at 12 months compared to baseline. Participants were divided equally into a low-dose group (3.15 million cells) and a high-dose group (6.30 million cells).

    • A9-DPC (TED-A9) consists of high-purity ventral midbrain dopaminergic progenitor cells derived from human embryonic stem cells (hESCs) under rigorous GMP conditions.
    • A total of 12 participants received bilateral putamen transplantation with either a low-dose (3.15 million cells; n = 6) or a high-dose (6.30 million cells; n = 6) of A9-DPC, with the last participant receiving treatment in February 2024.
    • At 12 months, the safety profile was favorable, with no tumorigenesis, overgrowth of transplanted cells, ectopic cell migration, or immune-mediated inflammation observed.
    • Clinical improvements were observed, along with evidence of cell survival and engraftment at the 12-month follow-up.
    • Increased dopamine transporter (DAT) signals in putamen, measured by [18F]FP-CIT PET, correlated with the observed improvements of motor function.

    The MDS-UPDRS Part III (off) score, a standard scale for assessing motor symptom severity in Parkinson’s disease, showed a mean decrease (improvement) of 12.7 points in the low-dose group and 15.5 points in the high-dose group at 12 months compared to baseline. There were also improvements in MDS-UPDRS Part I, II and IV scores. The MDS-UPDRS Total (off) score showed mean improvements of 29.0 points and 34.7 points in the low- and high-dose groups, respectively.

    Clinical improvements were further supported by changes in the Hoehn and Yahr stage, an ordinal scale categorizing disease severity based on motor function. On average, low-dose recipients improved (decreased) from stage 3.7 to 2.7, while high-dose recipients demonstrated a greater improvement from stage 3.8 to 2.2.

    A9-DPC also demonstrated favorable outcomes in other assessments, including the Non-Motor Symptoms Scale (NMSS), the Parkinson’s Disease Questionnaire-39 (PDQ-39) and the Schwab and England Activities of Daily Living Scale (SEADL). NMSS score improved by 31.7 points in the low-dose group and by 35.8 points in the high-dose group.

    [18F]FP-CIT PET imaging showed an overall increase in putamen DAT signals, with greater increases observed in the high-dose group, providing additional evidence for the underlying mechanism of action. Notably, there was a statistically significant correlation between improvements in MDS-UPDRS Part III (off) scores and increased DAT signal in the posterior dorsal putamen, supporting the hypothesis of synaptic restoration through engrafted cells.

    In terms of safety, the safety profile remained favorable. No treatment-emergent adverse events (TEAEs) related to the transplanted cells were reported. Tumorigenesis, cell overgrowth, or ectopic cell migration was not observed. Most of TEAEs were mild to moderate. One participant experienced an asymptomatic mild hemorrhage, but no neurological abnormalities or other serious side effects were observed.

    “Our data show a consistent positive trend throughout the study period, demonstrating the favorable safety and efficacy profiles. Importantly, increased DAT signals on PET imaging correlated with the observed behavioral recovery, which is very promising in terms of the mechanism of A9-DPC through neuroimaging.“ said Prof. Dong-Wook Kim of Yonsei University College of Medicine and CTO of S.BIOMEDICS. “We will continue to present additional data through our ongoing study.”

    About A9-DPC and Phase 1/2a clinical trial

    A9-DPC (also called TED-A9) is an investigational cell therapy designed to replace ventral midbrain-specific dopaminergic neurons lost in patients with Parkinson’s disease. These ventral midbrain-specific dopaminergic cells are derived from hESCs (human embryonic stem cells) by exclusively utilizing small molecules under strict GMP conditions. A9-DPC represents a significant advancement in the field, offering highly purified dopaminergic cells derived from hESCs. Through a stereotactic surgical procedure, these hESC-derived dopaminergic progenitor (precursor) cells are transplanted into three segments of the putamen: the anterior, middle, and posterior sections, with three tracks per each putamen. Bilateral putamina were treated in a single surgical procedure, with cells injected at three points within each track. After transplantation, the progenitor cells are expected to mature into dopaminergic neurons, enhancing neural connectivity and restoring motor function in patients.

    The Phase 1/2a clinical trial enrolled 12 participants diagnosed with Parkinson’s disease for more than 5 years who exhibited motor complications such as wearing off, freezing of gait, or dyskinesia. Participants ranged from 50 to 75 years old. An initial low-dose cohort (3.15 million cells) of three patients was first enrolled to assess initial safety including dose-limiting toxicity (DLT) over three months. After confirming safety, an additional three patients received the high dose (6.30 million cells) for similar evaluation. With continued safety confirmation, three more patients were enrolled in each dose group, totaling 12 participants. The final participant received A9-DPC in February 2024.

    The primary objective of the Phase 1/2a trial is to evaluate the safety and exploratory efficacy for up to two years post-transplantation, with safety follow-up continuing for an additional three years.

    About S.BIOMEDICS

    Established in 2005, S.BIOMEDICS Co., Ltd. is a leading innovator in stem cell therapy, specializing in regenerative medicine powered by data-driven biology. Leveraging two core platform technologies, S.BIOMEDICS is currently advancing seven cell therapy programs targeting intractable diseases. Several of its lead candidates are now in clinical development, demonstrating the company’s leadership in advancing cell-based medicine:

    • A9-DPC (TED-A9): Ventral midbrain-specific dopaminergic progenitor cells derived from hESCs for Parkinson’s disease (Phase 1/2a)
    • TED-N: PSA-NCAM-positive neural progenitor cells derived from hESCs for spinal cord injury (Phase 1/2a)
    • FECS-Ad: 3D MSC spheroids for critical limb ischemia (completed Phase 1/2a)

    As the foremost authority and trailblazer in Parkinson’s disease treatment in South Korea, S.BIOMEDICS is setting the national standard for cell therapy innovation.

    More Information about the Phase 1/2a clinical trial for Parkinson’s disease is available at ClinicalTrials.gov (NCT05887466).

    For more information about S.BIOMEDICS, visit https://www.sbiomedics.com/. S.BIOMEDICS is listed on the Korea Exchange and is also the founder and controller of S.THEPHARM (www.sthepharm.com), a corporation specializing in anti-aging products such as HA-Filler.

    Media contact

    Brand: S.BIOMEDICS

    Contact: Sarang Kim

    Email: ksr7744@sbiomedics.com

    Website: https://www.sbiomedics.com